<DOC>
	<DOCNO>NCT00277602</DOCNO>
	<brief_summary>Primary objective : - The primary objective study establish riluzole slows ( 1 ) decrease total functional capacity ( TFC ) , ( 2 ) increase motor score Unified Huntington 's Disease Rating Scale ( UHDRS ) well ( 3 ) increase combine score . Secondary objective : Secondary objective ass - change UHDRS subscales - number patient need antichoreic treatment time treatment initiate - safety/tolerability riluzole Huntington patient</brief_summary>
	<brief_title>Riluzole Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Clinical diagnosis Huntington 's disease CAG repeat length 36 UHDRS Motor score least 5 point UHDRS TFC score least 8 point , i.e . patient must independently ambulatory must require nursing care Females require negative blood pregnancy test inclusion Any form chorea Huntington 's disease Patients antichoreic treatment within one month prior entry foreseen require treatment within first 3 month randomization ( antichoreic medication prohibit entire study ) Other unacceptable prior/concomitant medication Uncontrolled major psychiatric disorder , particular uncontrolled major depression ( DSM IV definition ) Drug alcohol dependence and/or abuse ( DSM IV definition ) within past 6 month Any concomitant disease reasonable possibility interfere study Females breastfeeding , sterilize , least one year postmenopausal n't use adequate contraceptive method least one month prior study participation Participation another clinical study investigational drug within 30 day prior study screen Prior exposure riluzole ALT and/or AST and/or Total Bilirubin level great 1.5 time upper limit normal range , hepatic disease Gilbert 's disease Creatinine serum concentration 200 Âµmol/l ( resp . 2,3 mg/dl ) hematology parameter follow : Hemoglobin small 11 g/dl male resp . small 10 g/dl female , White Blood Cell small 3,5 x 10000000000/l</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>